Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 629pembrolizumab 559Magnetic Resonance Spectroscopy 539Carboplatin 423Cyclophosphamide 371Cisplatin 371Biopsy 357Paclitaxel 304Nivolumab 301Gemcitabine 299Radiotherapy 270Bevacizumab 238Dexamethasone 207fludarabine 205Docetaxel 189durvalumab 178atezolizumab 176Oxaliplatin 172Fluorouracil 167venetoclax 164Rituximab 164Pemetrexed 162Radiation 159Doxorubicin 159Capecitabine 158Radiosurgery 147Etoposide 137Ipilimumab 134Leucovorin 133Lenalidomide 130

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Clostridium perfringens epsilon-toxin × 90 days × Clear all
NCT07474090 2026-06-01

STEPS-BC

Wake Forest University Health Sciences

Phase NA Active not recruiting
120 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT05876923 2026-04-09

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

Mayo Clinic

Phase NA Recruiting
70 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡